Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Juan Pablo Frias; Michael A. Nauck; Joanna Van; Charles Benson; Ross Bray; Xuewei Cui; Zvonko Milicevic; Shweta Urva; Axel Haupt; Deborah A. Robins

doi:10.1111/dom.13979

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Diabetes Obesity and Metabolism ◽

10.1111/dom.13979 ◽

2020 ◽

Vol 22 (6) ◽

pp. 938-946 ◽

Cited By ~ 5

Author(s):

Juan Pablo Frias ◽

Michael A. Nauck ◽

Joanna Van ◽

Charles Benson ◽

Ross Bray ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Insulinotropic Peptide

Download Full-text

Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study

Journal of Diabetes Investigation ◽

10.1111/jdi.12749 ◽

2017 ◽

Vol 9 (3) ◽

pp. 558-566 ◽

Cited By ~ 1

Author(s):

Antonio Nino ◽

Inaha Okuda ◽

Timothy H Wilson ◽

Lynn Yue ◽

Hiromu Nakajima ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Review for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v2/review1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Decision letter for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Review for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v1/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

Diabetes Obesity and Metabolism ◽

10.1111/dom.12382 ◽

2014 ◽

Vol 16 (12) ◽

pp. 1257-1264 ◽

Cited By ~ 62

Author(s):

J. Reusch ◽

M. W. Stewart ◽

C. M. Perkins ◽

D. T. Cirkel ◽

J. Ye ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study

Diabetes Care ◽

10.2337/dc08-1961 ◽

2009 ◽

Vol 32 (7) ◽

pp. 1237-1243 ◽

Cited By ~ 84

Author(s):

M. A. Nauck ◽

R. E. Ratner ◽

C. Kapitza ◽

R. Berria ◽

M. Boldrin ◽

...

Keyword(s):

Type 2 Diabetes ◽

Body Weight ◽

Glycemic Control ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Decision letter for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v1/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Metabolic improvement with short‐term glucagon like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients type 2 diabetes: a randomized double‐blind placebo‐controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14480 ◽

2021 ◽

Author(s):

Annemie Stege Bojer ◽

Martin Heyn Sørensen ◽

Jenny Bjerre ◽

Peter Gæde ◽

Niels Vejlstrup ◽

...

Keyword(s):

Type 2 Diabetes ◽

Diastolic Dysfunction ◽

Receptor Agonist ◽

Controlled Trial ◽

Short Term ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Author response for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v2/response1 ◽

2020 ◽

Author(s):

Juan Pablo Frias ◽

Michael A Nauck ◽

Joanna Van ◽

Charles Benson ◽

Ross Bray ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Author Response ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Review for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v1/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text